Prevalence of Contraindications to Nirmatrelvir-Ritonavir Among Hospitalized Patients With COVID-19 at Risk for Progression to Severe Disease

JAMA Netw Open. 2022 Nov 1;5(11):e2242140. doi: 10.1001/jamanetworkopen.2022.42140.

Nicolas Hoertel^{1

2

3}, David R Boulware⁴, Marina Sánchez-Rico³, Anita Burgun⁵, Frédéric Limosin^{1

2

3}

¹ Université Paris Cité, Paris, France.
² INSERM U1266, Institut de Psychiatrie et Neuroscience de Paris, Paris, France.
³ Assistance Publique-Hôpitaux de Paris, DMU Psychiatrie et Addictologie, Service de Psychiatrie et Addictologie, Hôpital Corentin-Celton, Issy-les-Moulineaux, France.
⁴ Division of Infectious Diseases and International Medicine, Department of Medicine, University of Minnesota, Minneapolis.
⁵ INSERM, UMR S1138, Cordeliers Research Center, Université de Paris, Paris, France.

No abstract available

Plain language summary

This cohort study examines the prevalence of contraindications to nirmatrelvir-ritonavir in patients hospitalized with COVID-19.